[Treatment of myasthenia with adrencorticotrophins (ACTH and Synacthen). Apropos of 100 treatments in 25 patients].
D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D011188:Potassium / Q000652:urine; D012964:Sodium / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use; D013934:Thymectomy; D013945:Thymoma / Q000150:complications; D013953:Thymus Neoplasms / Q000150:complications
D002800:Cholinesterase Inhibitors; D013148:Spironolactone; D000324:Adrenocorticotropic Hormone; D012964:Sodium; D011188:Potassium
Traitement de la myasthénie par les adrénocorticotrophines (ACTH et synacthène). A propos de 100 cures chez 25 malades.